乙型病毒性肝炎相关晚期肝病的抗病毒治疗效果观察(1)
摘要：目的 分析抗病毒疗法治疗乙型病毒性肝炎相关晚期肝病的临床效果。方法 选取我院2016年1月～9月收治的乙型病毒性肝炎相关晚期肝病患者80例为研究对象，随机分为对照组和观察组，各40例。对照组患者行常规治疗，观察组患者行抗病毒治疗，比较两组治疗效果。结果 原发性肝癌患者中，对照组治疗有效率为60.00%，观察组治疗有效率为88.89%;肝硬化患者中，对照组治疗有效率为64.29%，观察组治疗有效率为92.31%;重型肝炎患者中，对照组治疗有效率为68.75%，观察组治疗有效率为94.44%，组间数据比较，差异均有统计学意义(P<0.05)。结论 针对乙型病毒性肝炎相关晚期肝病患者进行治疗时，采用抗病毒治疗疗法可以达到理想的治疗效果，有利于患者康复。
关键词：乙型病毒性肝炎;晚期肝病;抗病毒治疗;恩替卡韦
中图分类号：R512.62 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.07.036
, http://www.100md.com
文章编号：1006-1959(2019)07-0120-03
Abstract：Objective To analyze the clinical effect of antiviral therapy in the treatment of advanced liver disease associated with hepatitis B virus. Methods 80 patients with advanced hepatitis B associated with hepatitis B admitted to our hospital from January to September 2016 were enrolled in the study. They were randomly divided into control group and observation group， 40 cases each. Patients in the control group underwent routine treatment， and patients in the observation group underwent antiviral therapy， and the effects of the two groups were compared. Results In the patients with primary liver cancer， the effective rate of the control group was 60.00%， and the effective rate of the observation group was 88.89%. Among the patients with liver cirrhosis， the effective rate of the control group was 64.29%， and the effective rate of the observation group was 92.31%. Among the patients with hepatitis， the effective rate of the control group was 68.75%， and the effective rate of the observation group was 94.44%，the difference between the groups was statistically significant (P<0.05). Conclusion When treating patients with hepatitis B-related advanced liver disease， antiviral therapy can achieve the desired therapeutic effect and is beneficial to the rehabilitation of patients.
, 百拇医药
Key words：Hepatitis B;Advanced liver disease;Antiviral therapy;Entecavir
乙型病毒性肝炎(viral hepatitis type B)俗稱乙肝，是由于乙型肝炎病毒(HBV)感染引起的，属于我国常见传染病之一，上世纪九十年代全国病毒性肝炎血清学流行病学调查结果显示，我国约1.2亿慢性乙型肝炎病毒感染者，其中约3000万为慢性乙型肝炎患者，每年死于肝癌、肝硬化等与乙型肝炎相关疾病的人数超过30万人[1-3]。乙型病毒性肝炎病情发展到晚期，可能会导致重型肝炎、肝硬化甚至肝癌。乙肝相关晚期肝病的发病机制极其复杂，并发症多，病死率高，属于难治性疾病，就治疗而言暂无理想的方法，一般都是运用综合治疗，但是效果不佳，目前抗病毒疗法越来越得到了重视。本次研究选择我院80例乙型病毒性肝炎相关晚期肝病患者进行研究，旨在观察抗病毒疗法的临床效果，现报告如下。
1资料与方法, 百拇医药(马琳 田瑞民)
关键词：乙型病毒性肝炎;晚期肝病;抗病毒治疗;恩替卡韦
中图分类号：R512.62 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.07.036
, http://www.100md.com
文章编号：1006-1959(2019)07-0120-03
Abstract：Objective To analyze the clinical effect of antiviral therapy in the treatment of advanced liver disease associated with hepatitis B virus. Methods 80 patients with advanced hepatitis B associated with hepatitis B admitted to our hospital from January to September 2016 were enrolled in the study. They were randomly divided into control group and observation group， 40 cases each. Patients in the control group underwent routine treatment， and patients in the observation group underwent antiviral therapy， and the effects of the two groups were compared. Results In the patients with primary liver cancer， the effective rate of the control group was 60.00%， and the effective rate of the observation group was 88.89%. Among the patients with liver cirrhosis， the effective rate of the control group was 64.29%， and the effective rate of the observation group was 92.31%. Among the patients with hepatitis， the effective rate of the control group was 68.75%， and the effective rate of the observation group was 94.44%，the difference between the groups was statistically significant (P<0.05). Conclusion When treating patients with hepatitis B-related advanced liver disease， antiviral therapy can achieve the desired therapeutic effect and is beneficial to the rehabilitation of patients.
, 百拇医药
Key words：Hepatitis B;Advanced liver disease;Antiviral therapy;Entecavir
乙型病毒性肝炎(viral hepatitis type B)俗稱乙肝，是由于乙型肝炎病毒(HBV)感染引起的，属于我国常见传染病之一，上世纪九十年代全国病毒性肝炎血清学流行病学调查结果显示，我国约1.2亿慢性乙型肝炎病毒感染者，其中约3000万为慢性乙型肝炎患者，每年死于肝癌、肝硬化等与乙型肝炎相关疾病的人数超过30万人[1-3]。乙型病毒性肝炎病情发展到晚期，可能会导致重型肝炎、肝硬化甚至肝癌。乙肝相关晚期肝病的发病机制极其复杂，并发症多，病死率高，属于难治性疾病，就治疗而言暂无理想的方法，一般都是运用综合治疗，但是效果不佳，目前抗病毒疗法越来越得到了重视。本次研究选择我院80例乙型病毒性肝炎相关晚期肝病患者进行研究，旨在观察抗病毒疗法的临床效果，现报告如下。
1资料与方法, 百拇医药(马琳 田瑞民)